MAPT and Alzheimer disease: Given emerging evidence from clinical Aβ antibody trials [61], which support the targeting of soluble fibrillar Aβ species to consequently reduce tau pathology, further understanding the degree of interaction between Aβ and tau will provide greater insight into the mechanisms of AD-related pathogenesis.